151 related articles for article (PubMed ID: 11023518)
1. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells.
Li Y; Bendandi M; Deng Y; Dunbar C; Munshi N; Jagannath S; Kwak LW; Lyerly HK
Blood; 2000 Oct; 96(8):2828-33. PubMed ID: 11023518
[TBL] [Abstract][Full Text] [Related]
2. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells.
Wen YJ; Barlogie B; Yi Q
Blood; 2001 Mar; 97(6):1750-5. PubMed ID: 11238117
[TBL] [Abstract][Full Text] [Related]
3. In vitro priming of myeloma antigen-specific allogeneic donor T cells with idiotype pulsed dendritic cells.
Kim SB; Baskar S; Kwak LW
Leuk Lymphoma; 2003 Jul; 44(7):1201-8. PubMed ID: 12916873
[TBL] [Abstract][Full Text] [Related]
4. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.
Reichardt VL; Okada CY; Liso A; Benike CJ; Stockerl-Goldstein KE; Engleman EG; Blume KG; Levy R
Blood; 1999 Apr; 93(7):2411-9. PubMed ID: 10090953
[TBL] [Abstract][Full Text] [Related]
5. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses.
Osterborg A; Yi Q; Henriksson L; Fagerberg J; Bergenbrant S; Jeddi-Tehrani M; Rudén U; Lefvert AK; Holm G; Mellstedt H
Blood; 1998 Apr; 91(7):2459-66. PubMed ID: 9516146
[TBL] [Abstract][Full Text] [Related]
6. Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma.
Osterborg A; Henriksson L; Mellstedt H
Acta Oncol; 2000; 39(7):797-800. PubMed ID: 11145435
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in multiple myeloma: Id-specific strategies suggested by studies in animal models.
Corthay A; Lundin KU; Munthe LA; Frøyland M; Gedde-Dahl T; Dembic Z; Bogen B
Cancer Immunol Immunother; 2004 Sep; 53(9):759-69. PubMed ID: 15088126
[TBL] [Abstract][Full Text] [Related]
8. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.
Massaia M; Borrione P; Battaglio S; Mariani S; Beggiato E; Napoli P; Voena C; Bianchi A; Coscia M; Besostri B; Peola S; Stiefel T; Even J; Novero D; Boccadoro M; Pileri A
Blood; 1999 Jul; 94(2):673-83. PubMed ID: 10397734
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells.
Osterroth F; Garbe A; Fisch P; Veelken H
Blood; 2000 Feb; 95(4):1342-9. PubMed ID: 10666209
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells.
Dembic Z; Schenck K; Bogen B
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2697-702. PubMed ID: 10706628
[TBL] [Abstract][Full Text] [Related]
11. A mouse model for immunotherapy of myeloma.
Bogen B
Hematol J; 2002; 3(5):224-9. PubMed ID: 12391539
[TBL] [Abstract][Full Text] [Related]
12. [Induction of active antitumor immune response by myeloma idiotype protein-pulsed dendritic cells].
Yin XR; Zhang M; Luo YY; Lin X; He PC; Chen LM; Cai RB; Guo GL
Ai Zheng; 2005 Jun; 24(6):657-62. PubMed ID: 15946473
[TBL] [Abstract][Full Text] [Related]
13. Deletion of idiotype (Id)-specific T cells in multiple myeloma.
Bogen B; Schenck K; Munthe LA; Dembic Z
Acta Oncol; 2000; 39(7):783-8. PubMed ID: 11145433
[TBL] [Abstract][Full Text] [Related]
14. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells.
Märten A; Renoth S; von Lilienfeld-Toal M; Buttgereit P; Schakowski F; Glasmacher A; Sauerbruch T; Schmidt-Wolf IG
Haematologica; 2001 Oct; 86(10):1029-37. PubMed ID: 11602408
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
Curti A; Tosi P; Comoli P; Terragna C; Ferri E; Cellini C; Massaia M; D'Addio A; Giudice V; Di Bello C; Cavo M; Conte R; Gugliotta G; Baccarani M; Lemoli RM
Br J Haematol; 2007 Nov; 139(3):415-24. PubMed ID: 17910631
[TBL] [Abstract][Full Text] [Related]
16. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects.
Titzer S; Christensen O; Manzke O; Tesch H; Wolf J; Emmerich B; Carsten C; Diehl V; Bohlen H
Br J Haematol; 2000 Mar; 108(4):805-16. PubMed ID: 10792287
[TBL] [Abstract][Full Text] [Related]
17. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy.
Wen YJ; Min R; Tricot G; Barlogie B; Yi Q
Blood; 2002 May; 99(9):3280-5. PubMed ID: 11964294
[TBL] [Abstract][Full Text] [Related]
18. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma.
Liso A; Stockerl-Goldstein KE; Auffermann-Gretzinger S; Benike CJ; Reichardt V; van Beckhoven A; Rajapaksa R; Engleman EG; Blume KG; Levy R
Biol Blood Marrow Transplant; 2000; 6(6):621-7. PubMed ID: 11128812
[TBL] [Abstract][Full Text] [Related]
19. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
Hong S; Li H; Qian J; Yang J; Lu Y; Yi Q
Clin Exp Immunol; 2012 Nov; 170(2):167-77. PubMed ID: 23039887
[TBL] [Abstract][Full Text] [Related]
20. Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice.
Zeis M; Frenzke H; Schmitz N; Uharek L; Steinmann J
Bone Marrow Transplant; 2002 Feb; 29(3):213-21. PubMed ID: 11859393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
